Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Director/PDMR Shareholding

16 Dec 2020 18:15

RNS Number : 9209I
AstraZeneca PLC
16 December 2020
 

16 December 2020 18:15 GMT

 

Transaction by Person Discharging Managerial Responsibilities

Disclosure under Article 19 of the EU Market Abuse Regulation

 

AstraZeneca PLC (the Company) announced that, on 16 December 2020, it was notified of transactions in the Company's Ordinary Shares of $0.25 each by certain Persons Discharging Managerial Responsibilities (PDMRs) of the Company as set out below.

 

PDMR

Position

Nature of the transaction

Quantity

Price

Philip Broadley

Non-Executive Director

Purchase of Ordinary Shares

1,310

GB£76.25

Nazneen Rahman

Non-Executive Director

Purchase of Ordinary Shares

259

GB£76.78

Nazneen Rahman

Non-Executive Director

Purchase of Ordinary Shares

258

GB£76.79

 

 

 

The attached notification, made in accordance with the requirements of the EU Market Abuse Regulation, gives further detail.

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

 

 

Philip Broadley

2

 

Reason for the notification

 

a)

 

Position/status

 

 

Non-Executive Director

b)

 

Initial notification /Amendment

 

 

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

 

AstraZeneca PLC

b)

 

LEI

 

 

PY6ZZQWO2IZFZC3IOL08

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

 

a)

 

Description of the financial instrument, type of instrument

 

Identification code

 

 

Ordinary Shares of US$0.25 each in AstraZeneca PLC

 

 

GB0009895292

 

b)

 

Nature of the transaction

 

 

Purchase of AstraZeneca PLC Ordinary Shares

c)

 

Price(s) and volume(s)

 

 

 

Price(s)

 

Volume(s)

GB£76.25

1,310

 

 

d)

 

Aggregated information

 

 

- Aggregated volume

 

 

- Price

 

 

Not applicable - single transaction

 

e)

 

Date of the transaction

 

 

16 December 2020

f)

 

Place of the transaction

 

 

XLON

 

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

 

 

Nazneen Rahman

2

 

Reason for the notification

 

a)

 

Position/status

 

 

Non-Executive Director

b)

 

Initial notification /Amendment

 

 

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

 

AstraZeneca PLC

b)

 

LEI

 

 

PY6ZZQWO2IZFZC3IOL08

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

 

a)

 

Description of the financial instrument, type of instrument

 

Identification code

 

 

Ordinary Shares of US$0.25 each in AstraZeneca PLC

 

 

GB0009895292

 

b)

 

Nature of the transaction

 

 

Purchase of AstraZeneca PLC Ordinary Shares

c)

 

Price(s) and volume(s)

 

 

 

Price(s)

 

Volume(s)

GB£76.776

GB£76.791

259

258

 

 

d)

 

Aggregated information

 

 

- Aggregated volume

 

 

- Price

 

 

 

 

 

517

 

 

GB£76.784

e)

 

Date of the transaction

 

 

16 December 2020

f)

 

Place of the transaction

 

 

XLON

 

 

AstraZeneca

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.

Contacts

For details on how to contact the Investor Relations Team, please click here. For Media contacts, click here.

 

 

Adrian KempCompany Secretary

AstraZeneca PLC

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHUNRWRRAUUAAA

Related Shares

Back to RNS

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.